Non-small Cell Lung Cancer as a Chronic Disease - A Prospective Study from the Czech TULUNG Registry

Authors

BRATOVÁ Monika KARLÍNOVÁ Bára SKŘIČKOVÁ Jana PESEK Milos KOLEK Vitezslav KOUBKOVA Leona HRNCIARIK Michal KREJCI Jana BAŘINOVÁ Magda HAVEL Libor GRYGARKOVA Ivona BRAT Kristián

Year of publication 2020
Type Article in Periodical
Magazine / Source In vivo
MU Faculty or unit

Faculty of Medicine

Citation
Web http://dx.doi.org/10.21873/invivo.11783
Doi http://dx.doi.org/10.21873/invivo.11783
Keywords Non-small cell lung cancer; 2-year survival; modern-era treatment; personalized treatment; chronic disease
Description Aim: To compare survival outcomes in patients with non-small cell lung cancer (NSCLC) treated with modern-era drugs (antifolates, antiangiogenics, tyrosine kinase and anaplastic lymphoma kinase inhibitors, immunotherapy) with treatment initiation in 2011-12 and 2015-16, respectively. Patients and Methods: Prospective data from Czech TULUNG Registry (960 patients from 2011-12 and 512 patients from 2015-16) were analyzed. Kaplan-Meier analysis was used to estimate overall survival (OS) and progression free survival (PFS); Cox proportional hazards model to assess factors associated with 2-year survival. Results: Survival at 2 years was more frequent in cohort 2015-16 compared to cohort 201112 (43.2% vs. 24% for adenocarcinoma; p<0.001 and 28.7% vs. 11.8% for squamous-cell lung carcinoma; p=0.002). Assignment to cohort 2015-16 and treatment multilinearity (two or more lines in sequence) were associated with higher probability of 2-year survival (hazard ratio=0.666 and hazard ratio=0 .597 ; p<0.001). Comparison of 2-year survivors from both cohorts showed no differences. Conclusion: Survival at 2 years probability in stage IIIB-IV NSCLC doubled between 2011-12 and 2015-16; advanced-stage NSCLC may be considered a chronic disease in a large proportion of patients.

You are running an old browser version. We recommend updating your browser to its latest version.

More info